Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
出版年份 2021 全文链接
标题
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
作者
关键词
-
出版物
BMC CANCER
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-09
DOI
10.1186/s12885-021-07826-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Evolution of molecular targets in melanoma treatment
- (2020) Khanh Bao Tran et al. CURRENT PHARMACEUTICAL DESIGN
- Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma
- (2020) Khanh B. Tran et al. Pigment Cell & Melanoma Research
- Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
- (2020) Franz J. Hilke et al. Cancers
- Identification and characterization of two novel oncogenic mTOR mutations
- (2019) Avaniyapuram Kannan Murugan et al. ONCOGENE
- Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
- (2019) Jonathan A. Trujillo et al. Journal for ImmunoTherapy of Cancer
- A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
- (2018) Gabriele Romano et al. Cancer Discovery
- Melanoma
- (2018) Dirk Schadendorf et al. LANCET
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- PIK3CA -mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation
- (2017) Jillian M. Silva et al. Pigment Cell & Melanoma Research
- Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/ BRAF -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor
- (2016) Hélène Bonnevaux et al. MOLECULAR CANCER THERAPEUTICS
- The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis
- (2015) Lisa M. Ooms et al. CANCER CELL
- Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors
- (2015) Y. Kong et al. CLINICAL CANCER RESEARCH
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
- (2015) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
- (2015) Melanie Sweetlove et al. Frontiers in Oncology
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF -Mutated Melanoma
- (2014) Marian M. Deuker et al. Cancer Discovery
- Phosphoinositide 3-kinase and INPP4B in human breast cancer
- (2013) Micka C. Bertucci et al. Annals of the New York Academy of Sciences
- Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
- (2013) L. N. Kwong et al. CLINICAL CANCER RESEARCH
- Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
- (2013) Victoria Marsh Durban et al. JOURNAL OF CLINICAL INVESTIGATION
- A Tumor Suppressor Function for the Lipid Phosphatase INPP4B in Melanocytic Neoplasms
- (2013) Rolando Perez-Lorenzo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation
- (2012) Niki Tzenaki et al. FASEB JOURNAL
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma
- (2012) Austin Y. Shull et al. PLoS One
- Elucidating Distinct Roles for NF1 in Melanomagenesis
- (2012) Ophélia Maertens et al. Cancer Discovery
- A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types
- (2011) Stephen Jamieson et al. BIOCHEMICAL JOURNAL
- Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolismin vivo
- (2011) Greg C. Smith et al. BIOCHEMICAL JOURNAL
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Genetic alterations of PTEN in human melanoma
- (2011) Almass-Houd Aguissa-Touré et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase (PHLPP): A New Player in Cell Signaling
- (2011) Noel A. Warfel et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations
- (2010) Shingo Dan et al. CANCER RESEARCH
- Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
- (2010) Y. Shao et al. CANCER RESEARCH
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer-derived mutations in the regulatory subunit p85 of phosphoinositide 3-kinase function through the catalytic subunit p110
- (2010) M. Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
- (2009) R. Marone et al. MOLECULAR CANCER RESEARCH
- The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
- (2009) SubbaRao V. Madhunapantula et al. Pigment Cell & Melanoma Research
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started